March 8, 2018 / 1:26 PM / 7 months ago

BRIEF-Aeglea Bio Says ‍Dosing Of First Uveal And Cutaneous Melanoma Patients With Pegzilarginase In Open-Label Phase 1 Cohort Expansions​

March 8 (Reuters) - Aeglea Bio Therapeutics Inc:

* AEGLEA BIO THERAPEUTICS - ‍DOSING OF FIRST UVEAL AND CUTANEOUS MELANOMA PATIENTS WITH PEGZILARGINASE IN OPEN-LABEL PHASE 1 COHORT EXPANSIONS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below